An observational study in Endometrial Cancer, sponsored by University Hospital Hradec Kralove. Recruiting at 1 site in Czechia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University Hospital Hradec Kralove · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Endometrial Neoplasms with a site in Czechia — 9 open to participants now, 17 under way, 11 of them phase 3. Endometrial Neoplasms · Czechia.
Among the 25 studies in Endometrial Neoplasms with a site in Czechia, this one is the only one that started in 2026, is one of 6 observational ones, reaches primary completion later than 12 of the 16 other live ones, and was the 25th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →9 of the 25 studies in Endometrial Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Czechia, United States, Argentina and 25 more countries
Ages 18+ · Women only
BioNTech SE · Sites in Czechia, United States, Argentina and 24 more countries
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in Czechia, United States, Argentina and 31 more countries
Ages 18+ · Women only
Lukas Vanek · Sites in Czechia
Women only
Leiden University Medical Center · Sites in Czechia, Belgium, Canada and 4 more countries
Ages 18+ · Women only
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 14
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Median enrollment 480 across the 19 interventional studies, 240 across the 6 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 25 have an industry lead sponsor. The 10 most frequent:
University Hospital Hradec Kralove is the lead sponsor of 49 studies on the registry; 15 are open to participants now.
University Hospital Hradec Kralove has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Endometrial Neoplasms with a site in Czechia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT04291612Memorial Sloan Kettering Cancer CenterObservational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | 2027-02-26 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 5 to your calendar (.ics) → With an account.
Among the 25 studies in Endometrial Neoplasms with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:
Is there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.
Patients with histologicaly confirmed endometrial cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention
The accuracy of preoperative risk stratification
Time frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
Determination of specific groups for whom: 1) lymph node staging is crucial for changing risk category and adjuvant treatment decisions, and 2) lymph node staging could be safely omitted
Time frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.
Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 24 months is below that.
Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Hradec Kralove